Nilotinib With Radiation for High Risk Chordoma

Exclusion Criteria

• •Previous treatment with any other tyrosine kinase inhibitor
• •Previous treatment with radiotherapy to the primary or recurrent chordomas
• •Impaired cardiac function
• •Currently receiving treatment with strong CYP3A4 inhibitors
• •Requires anticoagulation with coumadin
• •Impaired GI function or GI disease that may significantly alter the absorption of study drug
• •Acute or chronic pancreatic disease
• •Known cytopathologically confirmed CNS infiltration
• •Another primary malignant disease which requires systemic treatment
• •Acute or chronic liver disease or severe renal disease considered unrelated to the cancer
• •History of significant congenital or acquired bleeding disorder unrelated to cancer
• •Major surgery within 4 weeks prior to Day 1 of the study or who have not recovered from prior surgery
• •Treatment with other investigational agents within 30 days of Day 1
• •History of non-compliance to medical regimens
• •Pregnant or breast-feeding